Articles by Ray Dogum

1. Chinese Competition And The Future Of Science: Insights From The U.S. Science Summit 7/24/2026

   At BiotechTV’s U.S. Science Summit, biotech leaders discussed China, AI, scientific storytelling, and what it will take to protect U.S. innovation.

2. Rhogam's Unconventional History And Why There Is No True Synthetic Replacement (Part 2 of 3) 7/17/2026

   Rhogam transformed Rh disease prevention, but its plasma-derived, polyclonal biology has resisted decades of synthetic anti-D replacement efforts.

3. iBio Aims To Complement GLP-1s By Preserving Muscle During Weight Loss With Myostatin Antibody 6/25/2026

   iBio has started clinical trials with a long-acting myostatin/GDF11 antibody that can make weight loss healthier and more durable for patients taking GLP-1 agonists.

4. How Rh Incompatibility Endangers Pregnancies And How Rhogam Helped My Family (Part 1 of 3) 6/15/2026

   Rh incompatibility can make pregnancy dangerous. Rhogam helped protect my family and stands as a powerful example of unconventional drug discovery.

5. 2026 Nucleate Boston Activator Cohort Interview: Arvin Soepriatna — TEEM Therapeutics 6/12/2026

   Arvin Soepriatna's TEEM Therapeutics is building predictive 3D human heart tissue models to improve cardiac drug screening, reduce risk earlier, and better flag cardiotoxicity.

6. 2026 Nucleate Boston Activator Cohort Interview: Ryan Posey & Anusha Manglik — Resilientia Therapeutics 6/11/2026

   Startup founders of Resilientia Tx discuss protecting cancer patients from radiation side effects, organ-on-a-chip discovery, Nucleate Boston, and early startup challenges.

7. 2026 Nucleate Boston Activator Cohort Interview: Dr. Chathuraka Jayasuriya — EnkaBio 6/11/2026

   Dr. Chat Jayasuriya discusses EnkaBio’s meniscus repair therapy, fundraising, Nucleate’s impact, CEO search, and tech transfer from Brown/Rhode Island Hospital.

8. 2026 Nucleate Boston Activator Cohort Interview: Chris Clifford — Mimic Therapeutics 6/10/2026

   Chris Clifford, founder of Mimic Therapeutics, describes the company’s mission as protecting cell therapies from immune rejection, with an initial focus on Type 1 diabetes.

9. 2026 Nucleate Boston Activator Cohort Interview: Carlos Ezio — Criocore 6/10/2026

   Carlos Ezio, co-founder and CEO of Criocore, a Harvard Medical School spinout developing bioprinted and frozen human tissue models for preclinical development. 

10. 2026 Nucleate Boston Activator Cohort Interview: Anna Kazatskaya — Fervid Therapeutics, previously Antozero 6/10/2026

    Anna Kazatskaya, CEO of Fervid Therapeutics is developing a novel peptide to treat pediatric epilepsy by increasing inhibitory synapses, backed by mouse data and a planned $2M pre-seed raise.